Jane Street Group, LLC Geron Corp Call Options Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2025 Aug 14, 2025	BUY	$1.18 - $1.62 $18,880 - $25,920	16,000 Added 140.35%	27,400 $38,000
Q1 2025 May 14, 2025	SELL	$1.59 - $3.6 $406,563 - $920,520	-255,700 Reduced 95.73%	11,400 $18,000
Q4 2024 Feb 14, 2025	BUY	$3.3 - $4.44 $78,540 - $105,672	23,800 Added 9.78%	267,100 $945,000
Q3 2024 Nov 14, 2024	BUY	$4.17 - $4.99 $1.01 Million - $1.21 Million	243,300 New	243,300 $1.1 Million
Q2 2021 Aug 16, 2021	SELL	$1.25 - $1.83 $144,625 - $211,731	-115,700 Reduced 82.58%	24,400 $34,000
Q2 2020 Aug 17, 2020	BUY	$1.05 - $2.18 $33,705 - $69,978	32,100 Added 29.72%	140,100 $305,000
Q3 2018 Nov 14, 2018	SELL	$1.76 - $6.38 $186,384 - $675,642	-105,900 Reduced 49.51%	108,000 $190,000
Q1 2018 May 15, 2018	BUY	$1.81 - $5.98 $387,159 - $1.28 Million	213,900 New	213,900 $909,000

287

493M

869K

564K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $510M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.